Screener
Bicara Therapeutics BCAX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by financing activities | 163,345 | 460 |
| Net (decrease)/increase in cash and cash equivalents | 226,777 | (27,646) |
| Cash and cash equivalents at beginning of period | 96,685 | 489,711 |
| Cash and cash equivalents at end of period | $323,462 | $462,065 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for tax | — | $72 |
| Non-cash investing and financing activities: | ||
| Offering costs included in accounts payable and accrued expenses | $190 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's cash & equivalents?
- Bicara Therapeutics (BCAX) reported cash & equivalents of $323.46M in Q1 2026.
- How has Bicara Therapeutics's cash & equivalents changed year-over-year?
- Bicara Therapeutics's cash & equivalents decreased by 30.0% year-over-year, from $462.07M to $323.46M.
- What is the long-term trend for Bicara Therapeutics's cash & equivalents?
- Over 3 years (2022 to 2025), Bicara Therapeutics's cash & equivalents has grown at a 185.4% compound annual growth rate (CAGR), from $4.16M to $96.69M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Bicara Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude